Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies
Prismo Metals Reports 4,811 g/t Silver and Confirms Deep Porphyry Copper Potential Beneath Historic Silver King Mine, near Resolution Copper in Arizona
Steadright Removes Titanbeach One Technical Report And Retains Qualified Geologist For New Technical Report
